{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:15:47Z","timestamp":1761844547637},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"vor","delay-in-days":1799,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1194\/jlr.m061903","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T23:57:23Z","timestamp":1442879843000},"page":"2124-2132","source":"Crossref","is-referenced-by-count":21,"title":["Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody"],"prefix":"10.1016","volume":"56","author":[{"given":"Krista M.","family":"Schroeder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan J.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bomie","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Pickard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor J.","family":"Wroblewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Kowala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick I.","family":"Eacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl.","key":"10.1194\/jlr.M061903_bib1","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M061903_bib2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1194\/jlr.CX00001-JLR200","article-title":"PCSK9 function and physiology","volume":"49","author":"Peterson","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M061903_bib3","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib4","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of PCSK9 in mice results in a low- density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M061903_bib5","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M061903_bib6","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M061903_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1194\/jlr.M061903_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1194\/jlr.M061903_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1194\/jlr.M061903_bib10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1194\/jlr.M061903_bib11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M061903_bib12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1194\/jlr.M800542-JLR200","article-title":"Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice","volume":"50","author":"Luo","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M061903_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology."},{"key":"10.1194\/jlr.M061903_bib14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M061903_bib15","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib16","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post- translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib17","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1194\/jlr.M049346","article-title":"Isolation and characterization of the circulating truncated form of PCSK9","volume":"55","author":"Han","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M061903_bib18","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib19","doi-asserted-by":"crossref","first-page":"43482","DOI":"10.1074\/jbc.M112.380618","article-title":"Furin-cleaved proprotein convertase subtilisin\/kexin type 9 (PCSK9) is active and modulates LDL receptor and serum cholesterol levels","volume":"287","author":"Lipari","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib20","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.M808363200","article-title":"Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants","volume":"284","author":"Bottomley","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure."},{"key":"10.1194\/jlr.M061903_bib22","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M061903_bib23","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M061903_bib24","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation."},{"key":"10.1194\/jlr.M061903_bib25","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jmb.2013.11.011","article-title":"An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo","volume":"426","author":"Schiele","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1194\/jlr.M061903_bib27","unstructured":"Davies, J., Darling, R. J., Allen, B. Antibodies to PCSK9 and uses thereof. United States patent US 20130071405 A1. 2013 Mar 21."},{"key":"10.1194\/jlr.M061903_bib28","unstructured":"Sleeman, M., Martin, J. H., Huang, T. T., MacDonald, D. High affinity human antibodies to PCSK9. United States patent US20100166768 A1. 2010 Jul 1."},{"key":"10.1194\/jlr.M061903_bib29","unstructured":"Jackson, S., Walker, N., Piper, D., Shan, B., Shen, W., Chan, J., King, C., Ketchem, R., Mehlin, C., Carabeo, T. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9). United States patent US20090326202 A1. 2009 Dec 31."},{"key":"10.1194\/jlr.M061903_bib30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0022-2275(20)42037-1","article-title":"Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography","volume":"32","author":"Kieft","year":"1991","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M061903_bib31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7150\/ijbs.3524","article-title":"An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes","volume":"8","author":"Zhang","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1194\/jlr.M061903_bib32","unstructured":"Liang, H., Abdiche, Y., Chaparro, R., Gomes, B., Hawkins, J., Pons, J., Qiu, X., Strop, P., Wang, Y. PCSK9 antagonists. United States patent US2010068199 A1. 2010 Mar 18."},{"key":"10.1194\/jlr.M061903_bib33","doi-asserted-by":"crossref","first-page":"11090","DOI":"10.1074\/jbc.M111.319764","article-title":"Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9","volume":"287","author":"Chaparro-Riggers","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib34","doi-asserted-by":"crossref","first-page":"10805","DOI":"10.1074\/jbc.M113.453373","article-title":"Characterization of proprotein convertase subtilisin\/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2)","volume":"288","author":"DeVay","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib35","doi-asserted-by":"crossref","first-page":"e0125127","DOI":"10.1371\/journal.pone.0125127","article-title":"Common proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitopes mediate multiple routes for internalization and function","volume":"10","author":"DeVay","year":"2015","journal-title":"PLoS One."},{"key":"10.1194\/jlr.M061903_bib36","doi-asserted-by":"crossref","first-page":"34296","DOI":"10.1074\/jbc.M109.039727","article-title":"Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation","volume":"284","author":"Tuli","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib37","doi-asserted-by":"crossref","first-page":"18609","DOI":"10.1074\/jbc.M115.647180","article-title":"Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9 convertase-mediated low density lipoprotein receptor degradation but interact with each other","volume":"290","author":"Butkinaree","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M061903_bib38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat. Biotechnol."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752035481X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752035481X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.M061903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T19:10:00Z","timestamp":1637435400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002222752035481X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S002222752035481X"],"URL":"https:\/\/doi.org\/10.1194\/jlr.m061903","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}